SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Biopharma Update on the Novel Coronavirus: April 27
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
April 27, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Job Trends
Clinical Catch-Up: April 20-24
Despite the domination of the news cycle by the COVID-19 pandemic, quite a number of biopharma companies reported on non-COVID-19 clinical trials last week, although there remains plenty of ongoing trial news related to the pandemic. Here’s a look.
April 24, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: April 24
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
April 24, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Sanofi Hits the Mark in Phase II MS Trial with Experimental BTK Inhibitor
The company said the treatment significantly reduced disease activity as measured by magnetic resonance imaging.
April 23, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Moderna’s COVID-19 Vaccine Clinical Trial Moves into 2nd Round of Dosing
On March 16, Moderna and the National Institute of Allergy and Infectious Disease (NIAID) began dosing patients with mRNA-1273, its vaccine candidate against COVID-19. The second round of dosing in healthy Seattle volunteers has now begun.
April 23, 2020
 · 
2 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: April 23
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 23, 2020.
April 23, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 22
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 22, 2020.
April 22, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
April 21, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 20, 2020.
April 20, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Pharm Country
Clinical Catch-Up: April 13-17
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
April 17, 2020
 · 
11 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
Triumvira Immunologics Announces First Patient Dosed in Phase I/II Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors
February 5, 2024
 · 
3 min read
Drug Development
Technoderma Medicines Phase 2 Clinical Trial of TDM-105795 Demonstrates Hair Growth in Androgenetic Alopecia
February 5, 2024
 · 
4 min read
Drug Development
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
February 5, 2024
 · 
9 min read
Drug Development
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
February 4, 2024
 · 
11 min read
Drug Development
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
February 3, 2024
 · 
12 min read
Drug Development
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
February 3, 2024
 · 
10 min read
Drug Development
Results of Phase II Study on Qilu Pharmaceutical’s Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy
February 2, 2024
 · 
4 min read
Drug Development
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
February 1, 2024
 · 
4 min read
Drug Development
U.S. FDA GRANTS THERADAPTIVE IDE APPROVAL FOR PHASE I/II CLINICAL TRIALS
February 1, 2024
 · 
5 min read
Drug Development
RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma and Metastatic Disease to the Lung
February 1, 2024
 · 
3 min read
Drug Development
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
February 1, 2024
 · 
8 min read
Drug Development
Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy
February 1, 2024
 · 
3 min read
Drug Development
Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026, a Monoclonal Antibody Targeting OX40, in Patients with Moderate to Severe Atopic Dermatitis
February 1, 2024
 · 
3 min read
Drug Development
Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation
February 1, 2024
 · 
5 min read
Drug Development
Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML
January 31, 2024
 · 
5 min read
Drug Development
InFlectis BioScience Completes Enrollment of Its Phase 2 Trial of IFB-088 for the Treatment of Amyotrophic Lateral Sclerosis; Anticipates Initial Results Later This Year
January 31, 2024
 · 
1 min read
Drug Development
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain
January 31, 2024
 · 
3 min read
Drug Development
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
January 30, 2024
 · 
3 min read
Drug Development
RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers
January 30, 2024
 · 
6 min read
Drug Development
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
January 30, 2024
 · 
6 min read
Load More